[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100387394":3},{"organization":4,"armGroups":7,"interventions":39,"overallOfficials":49,"centralContacts":54,"locations":64,"responsibleParty":81,"collaborators":10,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":10,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":91,"maxAge":10,"enrollmentInfo":92,"targetDuration":10,"studyType":95,"phases":10,"briefSummary":96,"conditions":97,"keywords":10,"overallStatus":67,"whyStopped":10,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Hunan Province Tumor Hospital","OTHER",[8,14,18,23,27,31,35],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1 Uncommon EGFR exon 19del",null,"patients with uncommon EGFR exon 19del",[13],"Drug: Third-generation EGFR-TKI",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2 EGFR exon 19delins","patients with EGFR exon 19delins",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3 EGFR exon 18del","patients with EGFR exon 18del",[22],"Drug: EGFR-TKI",{"label":24,"type":10,"description":25,"interventionNames":26},"Cohort 4 Common Uncommon Point Mutations","patients with common uncommon point mutations",[22],{"label":28,"type":10,"description":29,"interventionNames":30},"Cohort 5 Rare Uncommon Point Mutations","patients with rare uncommon point mutations",[22],{"label":32,"type":10,"description":33,"interventionNames":34},"Cohort 6 Compound Mutations Uncommon With Uncommon","patients with compound mutations uncommon with uncommon",[22],{"label":36,"type":10,"description":37,"interventionNames":38},"Cohort 7 Compound Mutations Uncommon With Common","patients with compound mutations uncommon with common",[22],[40,45],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":10},"DRUG","Third-generation EGFR-TKI","Third-generation EGFR-TKI including Osimertinib\u002FFurmonertinib\u002FAlmonertinib, etc.",[9,15],{"type":41,"name":46,"description":47,"armGroupLabels":48,"otherNames":10},"EGFR-TKI","All EGFR-TKI",[19,24,28,32,36],[50],{"name":51,"affiliation":52,"role":53},"Yongchang Zhang, MD","Hunan Cancer Hospital","PRINCIPAL_INVESTIGATOR",[55,60],{"name":51,"role":56,"phone":57,"phoneExt":58,"email":59},"CONTACT","+8613873123436","7+861383123436","zhangyongchang@csu.edu.cn",{"name":61,"role":56,"phone":62,"phoneExt":57,"email":63},"Nong Yang, MD","+8613055193557","yangnong0217@163.com",[65],{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"Yongchang Zhang","RECRUITING","Changsha","Hunan","410013","China","CN",{"type":74,"coordinates":75},"Point",[76,77],112.97087,28.19874,{"lat":77,"lon":76},[80],{"name":51,"role":56,"phone":57,"phoneExt":57,"email":59},{"type":53,"investigatorFullName":66,"investigatorTitle":82,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"professor","100387394","survival-outcome-of-egfr-tki-in-uncommon-egfr-mutant-advanced-nsclc-100387394",false,"NCT04324164","Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC","Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China","Inclusion Criteria:\n\n* 18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology\n\n  * Uncommon EGFR Mutant Advanced NSCLC\n\nExclusion Criteria:\n\n* Patients with contraindication of chemotherapy\n* Pregnant or breast feeding women","ALL","18 Years",{"count":93,"type":94},800,"ESTIMATED","OBSERVATIONAL","This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China",[98],"Non-small Cell Lung Cancer","2025-01-23",{"date":101,"type":102},"2025-01-27","ACTUAL",{"date":104,"type":102},"2020-03-24",{"date":106,"type":94},"2027-12-24",{"name":5,"class":6},1]